Best Immuno-Oncology Conference In UK In 2026
Immuno-Oncology & Biomarker Summit 2026
📍 London, UK
📅 16–17 March 2026
Event Overview
This two-day event is dedicated to advancing innovation in cancer immunotherapy and biomarker science. The agenda will cover the latest in antibody-drug conjugates (ADCs), bispecific antibodies, cellular therapies, immune checkpoint inhibitors, and novel combination strategies, along with insights into pre-clinical research, translational approaches, and the evolution of personalized immunotherapy.
A strong emphasis will be placed on biomarker discovery, immune monitoring, vaccine development, and the integration of multi-omic platforms. Through cutting-edge sessions and expert-led discussions, the summit will highlight how scientific breakthroughs are reshaping oncology and driving the development of more precise, effective cancer treatments.
The Biomarker Blueprint for Immuno Oncology
Explore The Key Highlights
Next-Generation Immunotherapies
ADCs, bispecific antibodies, and cellular therapies
Biomarker-Driven Precision Oncology
From discovery to clinical impact
Strategic Combination Approaches
Enhancing efficacy and overcoming resistance
Translational Research & Immune Monitoring
Preclinical models and real-time technologies for better decision-making
Biomarker Integration in IO Trials
Advancing cancer vaccines and oncolytic viruses
Who Should Attend
Research & Development (R&D):
Preclinical Research
Translational Research
Biomarker Discovery
Target Identification & Validation
Clinical Development:
Clinical Operations
Medical Affairs
Clinical Pharmacology
Early/Translational Clinical Programs
Translational Medicine:
Clinical Biomarker Teams
Genomics/Proteomics Analysis
Companion Diagnostics Development
Regulatory Affairs:
Regulatory Science
Companion Diagnostic Submissions
Health Authority Engagement
Who Should Attend
Immuno-Oncology
Biomarkers
Cell Therapies
Antibodies
Translational Research
Diagnostics
Precision Medicine
Clinical Trials
Drug Development
Commercialization
Cancer Vaccines
Oncolytic Viruses
Genomics
Bioinformatics
Investment
Final Decision Makers
Chief Executive Officer
Chief Scientific Officer
President
Vice President
Executive Director
Assoicate/Senior Director
Manager/Sr. Manager
Head of Department
Key Department
Research & Development (R&D):
Preclinical Research
Translational Research
Biomarker Discovery
Target Identification & Validation
Clinical Development:
Clinical Operations
Medical Affairs
Clinical Pharmacology
Early/Translational Clinical Programs
Translational Medicine:
Clinical Biomarker Teams
Genomics/Proteomics Analysis
Companion Diagnostics Development
Regulatory Affairs:
Regulatory Science
Companion Diagnostic Submissions
Health Authority Engagement
PROCUREMENT BUDGET
- 12% US $500,000 | US $1 million
- 29% US $100,000 | US $500,000
- 34% Less than US $100,000
- 25% More than US $1 million
SECTORS
BY JOB FUNCTION
Why Attend
Exclusive Insights
Latest advances in immuno-oncology, biomarkers, and precision oncology.
Collaboration
Connect with pharma, biotech, and academic leaders.
Combination Strategies
Explore checkpoint inhibitors, ADCs, and cell therapies.
Biomarker Integration
Personalization, trial optimization, and patient selection.
Regulatory Trends
Updates on global frameworks for IO and biomarker-based therapies.
Final Decision Makers
Connect With The Entire Regional Ecosystem
Under One Roof
Industry Stakeholders
Chief Executive Officer
Final Decision Makers
Chief Executive Officer
Chief Scientific Officer
Director
Chief Medical Officer
Sr. Manger
Vice President
Manager
Executive Director
2026 UK Edition Speakers
From Immuno-Oncology Visionaries
to Biomarker Science Pioneers
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Agenda
09:00 AM – 09:30 AM
Charles Makin, Head, RWE, Epidemiology, US, Boehringer Ingelheim
Agile RWE as a Strategic Lever in the Evolving Market Access Landscape
09:30 AM – 10:30 AM
Chitra Lele, Consulting Leader, Life Sciences, NTT DATA
Prasad Dindigal, Consulting Leader, Life Sciences, NTT DATA
11:15 AM – 11:40 AM
Beni Turner, Director of Real-World Clinical Insights, Magnolia Market Access
11:15 AM – 11:40 AM
Beni Turner, Director of Real-World Clinical Insights, Magnolia Market Access
11:15 AM – 11:40 AM
Beni Turner, Director of Real-World Clinical Insights, Magnolia Market Access
09:00 AM – 09:30 AM
Charles Makin, Head, RWE, Epidemiology, US, Boehringer Ingelheim
Agile RWE as a Strategic Lever in the Evolving Market Access Landscape
09:30 AM – 10:30 AM
Chitra Lele, Consulting Leader, Life Sciences, NTT DATA
Prasad Dindigal, Consulting Leader, Life Sciences, NTT DATA
11:15 AM – 11:40 AM
Beni Turner, Director of Real-World Clinical Insights, Magnolia Market Access
11:15 AM – 11:40 AM
Beni Turner, Director of Real-World Clinical Insights, Magnolia Market Access
11:15 AM – 11:40 AM
Beni Turner, Director of Real-World Clinical Insights, Magnolia Market Access
11:15 AM – 11:40 AM
Beni Turner, Director of Real-World Clinical Insights, Magnolia Market Access
Our Esteemed Sponsors & Exhibitors
Associate Sponsor
Media Partners
LISTING PARTNERS​
Past Edition Sponsors







Why Sponsor?
Dedicated Prime Speaking Slot
Exhibition Opportunity
One-to-One Meetings
Pre-Qualified Leads
High-Level Networking
Brand Impact
Why Sponsor?

Dedicated Prime
Speaking Slot

Exhibition
Opportunity

Pre-Scheduled
One-to-One Meetings

Pre-Qualified
Leads

High-Level
Networking

Brand
Impact




View The Glimpses Of Our Past Edition
EVIDENCE 360 Summit 2025 – Frankfurt
Blockchain After Dark
The HODL
After-party
in an electrifying atmosphere of innovation and celebration.
Hear What Are Sponsors Have to Say About Us
Evidence 360 USA Edition
Elevate your brand where crypto’s most influential minds connect beyond the conference floor.
Venue
Contact Our Team Today
in an electrifying atmosphere of innovation and celebration.
Partnerships